Fischer Medical Ventures Reports No Deviation in ₹358.45 Crore Use

Fischer Medical Ventures Ltd reported no deviation in the use of its ₹358.45 crore preferential issue proceeds for the quarter ended September 30, 2026, according to Infomerics' monitoring report. The company had utilised ₹332.56 crore by the reporting date, while ₹25.89 crore remained unutilised in a sweep fixed deposit.

What did the monitoring report say about Fischer Medical Ventures' issue proceeds?

Infomerics' monitoring report stated that Fischer Medical Ventures had not deviated from the stated use of proceeds raised through its preferential issue. The report covered the quarter ended September 30, 2026 and reviewed the deployment of the ₹358.45 crore raised by the company.

Of the total proceeds, ₹332.56 crore had been used as of September 30, 2026. The unutilised balance of ₹25.89 crore was held in a sweep fixed deposit. The disclosure did not indicate any diversion or use outside the purposes stated for the preferential issue.

A monitoring agency report is a regulatory disclosure that gives shareholders visibility into how a company is deploying funds raised through specified capital-raising transactions. In this case, the reported absence of deviation is the key finding, as the bulk of the issue proceeds had already been utilised by the end of the September quarter.

When did Fischer Medical Ventures consider its September-quarter results?

Fischer Medical Ventures scheduled a board meeting for November 14, 2026, through video conferencing, to consider and approve unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The board-meeting notice was filed on November 11, 2026.

The company also stated that its trading window for designated persons and related parties would remain closed until 48 hours after the declaration of the financial results. This is a standard restriction intended to limit trading while unpublished price-sensitive financial information is being considered and disclosed.

The September quarter covered July 1, 2026 to September 30, 2026. The monitoring report therefore provides a capital-utilisation update for the same reporting period for which the board was scheduled to consider financial results.

What is the recent financial context for Fischer Medical Ventures?

Fischer Medical Ventures' latest reported quarterly financial figures before the September-quarter board meeting were for Q1 FY27, covering April to June 2026. Consolidated revenue from operations was ₹81.9 crore, up 249.4% year on year and down 16.2% sequentially from Q4 FY26.

Consolidated net profit for Q1 FY27 was ₹3.8 crore, compared with ₹5 crore in Q1 FY26. The company had reported a loss of ₹7.1 crore in Q4 FY26, meaning the Q1 FY27 result represented a return to profit on a sequential basis.

For the comparable Q2 FY26 period ended September 2025, the information provided cites revenue of ₹86.31 crore and profit of ₹13.90 crore. These figures provide a reported historical base for assessing the September 2026 quarter when the company releases the relevant approved results.

Why does the utilisation update matter to investors?

The report gives investors a direct update on funds raised through the preferential issue. With ₹332.56 crore, or most of the ₹358.45 crore proceeds, reported as utilised, the remaining balance was limited to ₹25.89 crore at September 30, 2026. The balance being held in a sweep fixed deposit also identifies where the unutilised funds were parked.

For shareholders, the disclosure should be assessed alongside subsequent financial results and future company filings. The monitoring report confirms compliance with the stated use of proceeds as of the reporting date, but it does not by itself provide a view on operating performance, profitability, future revenue or returns from the deployment of funds.

The company had earlier reported audited standalone and consolidated results for the year ended March 31, 2026. Its statutory auditors issued an unmodified opinion on those financial statements. The board also recommended a final dividend of ₹0.05 per equity share for FY26, subject to shareholder approval.

Conclusion

Fischer Medical Ventures' September 2026 monitoring report records no deviation in the use of ₹358.45 crore raised through its preferential issue. By September 30, 2026, ₹332.56 crore had been utilised and ₹25.89 crore remained in a sweep fixed deposit, providing a clear record of the proceeds' status.

The next relevant disclosure is the company's approved unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026, which its board was scheduled to consider on November 14, 2026. Investors can track those results alongside future updates on the remaining unutilised proceeds.